Immunovant, Inc. IMVT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s additional paid-in capital?
- Immunovant, Inc. (IMVT) reported additional paid-in capital of $2.6B in Q1 2026.
- How has Immunovant, Inc.'s additional paid-in capital changed year-over-year?
- Immunovant, Inc.'s additional paid-in capital increased by 33.5% year-over-year, from $1.95B to $2.6B.
- What is the long-term trend for Immunovant, Inc.'s additional paid-in capital?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s additional paid-in capital has grown at a 34.5% compound annual growth rate (CAGR), from $590.43M to $2.6B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.